Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in pharmaceutical innovation.

One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to address that disease,” Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer said.

Google DeepMind's drug discovery company, Isomorphic Labs, is gearing up to launch the human trials of its AI-designed drugs.

Google DeepMind’s spin-off Isomorphic Labs says it’s almost ready to begin human testing for AI-designed drugs. Built on the success of AlphaFold, the company aims to speed up drug development in fields like cancer and immunology using artificial intelligence.